Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod

The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was...

Descripción completa

Detalles Bibliográficos
Autores principales: Krbot Skorić, Magdalena, Rogić, Dunja, Lapić, Ivana, Šegulja, Dragana, Habek, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629510/
https://www.ncbi.nlm.nih.gov/pubmed/34920248
http://dx.doi.org/10.1016/j.msard.2021.103435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629510/
https://www.ncbi.nlm.nih.gov/pubmed/34920248
http://dx.doi.org/10.1016/j.msard.2021.103435

Ejemplares similares